---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-119402"
form_type: "8-K"
ticker: "BNTC"
cik: "0001808898"
company_name: "Benitec Biopharma Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T09:48:27.524245+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Benitec Biopharma reports Q3 FY2025 net loss of $9.4M; cash $103.6M; BB-301 low-dose cohort completed

## Summary
- Net loss of $9.4M ($0.24/share) vs $4.3M ($0.23/share) in prior year; expenses rose to $10.2M on higher R&D and G&A.
- Cash and cash equivalents $103.6M as of March 31, 2025, up from $50.9M at June 30, 2024.
- BB-301: sixth and final subject in Cohort 1 (low dose) treated safely in April 2025; enrollment at higher dose expected later this year.
- Additional clinical study updates for Cohort 1 subjects planned for Q4 calendar 2025.

## SEC filing metadata
- accession: 0001193125-25-119402
- form_type: 8-K
- ticker: BNTC
- cik: 0001808898
- company_name: Benitec Biopharma Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808898/000119312525119402/0001193125-25-119402-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808898/000119312525119402/d52557d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-119402
- JSON: https://secwatch.observer/filing/0001193125-25-119402.json
- Plain text: https://secwatch.observer/filing/0001193125-25-119402.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.